Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine
Silo Pharma, Inc. (OTCQB: SILO) announced positive results from an animal study demonstrating its topical Ketamine formulation's effectiveness in reducing neuropathic nerve pain. The study showed a significant reduction in both allodynia and hyperalgesia using its patented delivery system in partnership with Zylo Therapeutics. Notably, day seven and day nine evaluations showed no erythema or swelling, indicating a favorable safety profile, which is promising for upcoming toxicology studies. CEO Eric Weisblum emphasized the potential benefits for patients with Fibromyalgia and Rheumatoid Arthritis.
- Successful demonstration of the Ketamine topical formulation reducing nerve pain.
- Patent-protected delivery system shows effectiveness in animal studies.
- No adverse effects (erythema or swelling) reported on day seven and nine, indicating good safety profile.
- Potential therapeutic benefits for Fibromyalgia and Rheumatoid Arthritis patients.
- None.
Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system
ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study.
Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study.
Eric Weisblum, CEO of Silo Pharma, commented, “These positive results of our study show that Silo is able to successfully formulate and deliver ketamine topically at reduced dosage to achieve its endpoint of pain reduction. This data is extremely promising for patients suffering from Fibromyalgia and Rheumatoid Arthritis. Additionally, I am delighted to report that Day seven and Day nine scores averaged zero (no erythema or swelling present) for all groups, which bodes extremely well for our planned toxicology study.”
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com
Safe Harbor and Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events, or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.
Investor Relations Contact:
Hayden IR
Brett Maas
646-536-7331
Email: brett@haydenir.com
FAQ
What results did Silo Pharma's Ketamine study produce?
What are the implications of Silo Pharma's recent study for patients?
Who partnered with Silo Pharma for the Ketamine delivery system?
What is the stock symbol for Silo Pharma?
